Skip to content

May 1, 2026

Home
Signal News
Biopharma Brief
Week in Review
Contact

Light/Dark Button

Search for:

Home
Regulatory
UniQure, in ‘symbolic’ win, to seek UK approval of Huntington’s gene therapy

Regulatory

UniQure, in ‘symbolic’ win, to seek UK approval of Huntington’s gene therapy

BioPharma Dive

News of the submission, which would be the first for UniQure s closely watched treatment, comes as the therapy faces an uncertain future in the U.S.

Read full story

pharminent April 30, 2026 (Last updated: May 1, 2026)

BioPharma Dive

News of the submission, which would be the first for UniQure s closely watched treatment, comes as the therapy faces an uncertain future in the U.S.

Read full story

Post navigation

Previous: Lilly posts another ‘blowout quarter’ as focus turns to Foundayo launch

Next: Parexel buys Vitrana to boost patient safety toolkit

Related Stories

Regulatory

FDA’s ODAC delivers one loss, one win for AstraZeneca

pharminent May 1, 2026

Regulatory

Axsome receives FDA approval for Auvelity to treat Alzheimer’s agitation

pharminent May 1, 2026

Regulatory

FDA Approves First Non-Antipsychotic Drug to Treat Agitation Associated with Dementia

pharminent April 30, 2026

You May Have Missed

Manufacturing

Novartis unveils North Carolina API plant as final piece of $23B US expansion

pharminent May 1, 2026

Pipeline

Amgen positions MariTide as potential ‘best monthly’ obesity drug

pharminent May 1, 2026

Regulatory

FDA’s ODAC delivers one loss, one win for AstraZeneca

pharminent May 1, 2026

Regulatory

Axsome receives FDA approval for Auvelity to treat Alzheimer’s agitation

pharminent May 1, 2026

Copyright © 2026 All rights reserved. | ReviewNews by AF themes.